Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Isoniazid | Research article

Treatment outcomes of drug resistant tuberculosis patients in Morocco: multi-centric prospective study

Authors: Mariam El Hamdouni, Jamal Eddine Bourkadi, Jouda Benamor, Mohammed Hassar, Yahia Cherrah, Samir Ahid

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Drug resistant tuberculosis is a major public health problem in Morocco and worldwide. Treatment outcome of drug resistant tuberculosis is poor and requires a long period of treatment with many toxic and expensive antituberculosis drugs. The aim of this study is to evaluate treatment outcomes of drug resistant tuberculosis and to determine predictors of poor treatment outcomes in a large region of Morocco.

Methods

It is a multi-centric observational cohort study conducted from January 01, 2014 to January 01, 2016. A questionnaire was established to collect data from clinical charts of patients with confirmed resistant TB. The study was carried out in all the 11 centers located in the Rabat-Salé-Kénitra region of Morocco where drug resistant tuberculosis is treated. Treatment outcomes were reported and the definitions and classifications of these outcomes were defined according to the WHO guidelines. Univariate and multivariate logistic regression were conducted to determine factors associated with poor drug resistant tuberculosis treatment outcomes in Morocco.

Results

In our study, 101 patients were treated for drug resistant tuberculosis between January 01, 2014 and January 01, 2016. Patients’ age ranged from 9.5 to70 years; 72patients (71.3%) were male and 80 patients (79.2%) were living in urban areas. Thirty two patients were smokers, 74 patients had multidrug-resistant tuberculosis, 25 patients had rifampicin resistance and 2 patients had isoniazid resistance. Treatment outcomes of tuberculosis patients were as follows: 45 patients were cured (44.5%), 9 completed treatment (8.9%), 5 patients died before completing the treatment, 35 patients were lost to follow up (34.6%) and 7 patients had treatment failure. In the multivariate analysis, being a smoker is an independent risk factor for poor treatment outcomes, (p-value = 0.015, OR = 4.355, IC [1.327–14.292]).

Conclusion

Treatment success outcomes occurred in more than half of the cases, which is lower than the World Health Organization target of at least a 75% success rate. A significant number of patients abandoned their treatment before its completion. These dropouts are a serious public health hazard that needs to be addressed urgently.
Literature
1.
go back to reference World Health Organization. Global Tuberculosis Report. 2017. World Health Organization. Global Tuberculosis Report. 2017.
4.
go back to reference Ministère-de-la-Santé-du-Maroc. Plan Stratégique national pour la prévention et le contrôle de la tuberculose au Maroc 2018–2021. Ministère-de-la-Santé-du-Maroc. Plan Stratégique national pour la prévention et le contrôle de la tuberculose au Maroc 2018–2021.
6.
go back to reference World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis. WHO progress report 2011. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis. WHO progress report 2011.
7.
go back to reference Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, et al. Epidemiology of antituberculosis drugs resistance (the global project on anti-tuberculosis drug ResistanceSurveillance): an updated analysis. Lancet. 2006;368(9553):2142–54.CrossRef Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, et al. Epidemiology of antituberculosis drugs resistance (the global project on anti-tuberculosis drug ResistanceSurveillance): an updated analysis. Lancet. 2006;368(9553):2142–54.CrossRef
8.
go back to reference Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in antituberculosis drugs. N Engl J Med. 2001;344(17):1294–303.CrossRef Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in antituberculosis drugs. N Engl J Med. 2001;344(17):1294–303.CrossRef
9.
go back to reference Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, et al. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv oblast, Ukraine. BMC Infectious Diseases. 2017;17:129.CrossRef Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, et al. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv oblast, Ukraine. BMC Infectious Diseases. 2017;17:129.CrossRef
10.
go back to reference Tachfouti N, Nejjari C, Benjelloun MC, Berraho M, Elfakir S, et al. Association between smoking status, other factors and tuberculosis treatment failure in Morocco. Int J Tuberc Lung Dis. 2011;15:838–43.CrossRef Tachfouti N, Nejjari C, Benjelloun MC, Berraho M, Elfakir S, et al. Association between smoking status, other factors and tuberculosis treatment failure in Morocco. Int J Tuberc Lung Dis. 2011;15:838–43.CrossRef
11.
go back to reference Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug resistant tuberculosis under DOTS-plus: a systematic review and meta-analysis of published studies. Infectious Diseases of Poverty. 2017;6:7.CrossRef Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug resistant tuberculosis under DOTS-plus: a systematic review and meta-analysis of published studies. Infectious Diseases of Poverty. 2017;6:7.CrossRef
12.
go back to reference Alene KA, Yi H, Viney K, McBryde ES, Yang K, Bai L, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis. 2017;17:573.CrossRef Alene KA, Yi H, Viney K, McBryde ES, Yang K, Bai L, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis. 2017;17:573.CrossRef
13.
go back to reference Population légale d'après les résultats du RGPH 2014 sur le Bulletin officiel N° 6354" (pdf). Haut-Commissariat au Plan (in Arabic). Retrieved 11-07-2015. Population légale d'après les résultats du RGPH 2014 sur le Bulletin officiel N° 6354" (pdf). Haut-Commissariat au Plan (in Arabic). Retrieved 11-07-2015.
14.
go back to reference WHO. World Health Organisation Policy guidance on drug-susceptibility testing of second-line antituberculous drugs Geneva. 2008. WHO. World Health Organisation Policy guidance on drug-susceptibility testing of second-line antituberculous drugs Geneva. 2008.
15.
go back to reference WHO. Definitions and reporting framework for tuberculosis – 2013 revision (updated 2014). Geneva: Switzerland World Health Organization; 2013. WHO. Definitions and reporting framework for tuberculosis – 2013 revision (updated 2014). Geneva: Switzerland World Health Organization; 2013.
17.
go back to reference Bastos ML, Cosme LB, Fregona G, Prado TN, Bertolde AI, Zandonade E, et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 2017;17:718.CrossRef Bastos ML, Cosme LB, Fregona G, Prado TN, Bertolde AI, Zandonade E, et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 2017;17:718.CrossRef
18.
go back to reference Dal T, Özcan N, Tekin R, Tekin A, Çelen MK, Özekinci T. Antituberculosis drug resistance in southeast of Turkey. ActaMedicaMediterranea 2013; 29: 41–46. Dal T, Özcan N, Tekin R, Tekin A, Çelen MK, Özekinci T. Antituberculosis drug resistance in southeast of Turkey. ActaMedicaMediterranea 2013; 29: 41–46.
19.
go back to reference Ibrahim E, Baess AI, Al Messery MA. Pattern of prevalence, risk factors and treatment outcomes among Egyptian patients with multidrug resistant tuberculosis. Egyptian Journal of Chest Diseases and Tuberculosis. 2017;66:405–11.CrossRef Ibrahim E, Baess AI, Al Messery MA. Pattern of prevalence, risk factors and treatment outcomes among Egyptian patients with multidrug resistant tuberculosis. Egyptian Journal of Chest Diseases and Tuberculosis. 2017;66:405–11.CrossRef
20.
go back to reference Delgado KC, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nuñez-Garbin A, et al. Factors associated with antituberculosis medication adverse effects: a case-control study in Lima, Peru. PLoS One. 2011;6(11):e27610.CrossRef Delgado KC, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nuñez-Garbin A, et al. Factors associated with antituberculosis medication adverse effects: a case-control study in Lima, Peru. PLoS One. 2011;6(11):e27610.CrossRef
21.
go back to reference Seliem Ibrahiem M.I. Detection of extensively drug resistant tuberculosis MD thesis, Faculty of Medicine, Alexandria University. 2012. Seliem Ibrahiem M.I. Detection of extensively drug resistant tuberculosis MD thesis, Faculty of Medicine, Alexandria University. 2012.
22.
go back to reference Gomes M, Correia A, Mendonca D, Duarte R. Risk factors for drug-resistant tuberculosis. J Tuberc Res. 2014;2:111–8.CrossRef Gomes M, Correia A, Mendonca D, Duarte R. Risk factors for drug-resistant tuberculosis. J Tuberc Res. 2014;2:111–8.CrossRef
23.
go back to reference Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high treatment success for multidrugresistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia-an observational cohort study. Thorax. 2015;70:1181–8.CrossRef Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high treatment success for multidrugresistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia-an observational cohort study. Thorax. 2015;70:1181–8.CrossRef
24.
go back to reference Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, et al. Transmission of MDR and XDR tuberculosis in Shanghai. China PLoS ONE. 2009;4:e4370.CrossRef Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, et al. Transmission of MDR and XDR tuberculosis in Shanghai. China PLoS ONE. 2009;4:e4370.CrossRef
25.
go back to reference Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W, et al. Multidrug-resistant tuberculosis in patient without HIV infection. N Engl J Med. 1995;333:907–11.CrossRef Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W, et al. Multidrug-resistant tuberculosis in patient without HIV infection. N Engl J Med. 1995;333:907–11.CrossRef
26.
go back to reference Diel R, Nieman S. Outcome of tuberculosis treatment in Hamburg: a survey, 1997–2001. Int J Tuberc Lung Dis. 2003;7:124–31.PubMed Diel R, Nieman S. Outcome of tuberculosis treatment in Hamburg: a survey, 1997–2001. Int J Tuberc Lung Dis. 2003;7:124–31.PubMed
27.
go back to reference Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, et al. Treatment outcomes and follow-up of multidrug-resistant tuberculosis patients, west coast/winelands, South Africa 1992-2002. Int J Tuberc Lung Dis. 2008;12:1182–9.PubMed Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, et al. Treatment outcomes and follow-up of multidrug-resistant tuberculosis patients, west coast/winelands, South Africa 1992-2002. Int J Tuberc Lung Dis. 2008;12:1182–9.PubMed
28.
go back to reference Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004;8:361–8.PubMed Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004;8:361–8.PubMed
29.
go back to reference Elmi OS, Habsah H, Sarimah A, Zuki mat Jeab M, Zilfalil BA, Naing NN. Treatment outcomes of patients with multidrug-resistant tuberculosis (MDR-TB) compared with non-MDR-TB infections in peninsular Malaysia. Malays J Med Sci. 2016;23(4):17–25.PubMedPubMedCentral Elmi OS, Habsah H, Sarimah A, Zuki mat Jeab M, Zilfalil BA, Naing NN. Treatment outcomes of patients with multidrug-resistant tuberculosis (MDR-TB) compared with non-MDR-TB infections in peninsular Malaysia. Malays J Med Sci. 2016;23(4):17–25.PubMedPubMedCentral
30.
go back to reference Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45:1290–5.CrossRef Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45:1290–5.CrossRef
31.
go back to reference Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17:299–307.CrossRef Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17:299–307.CrossRef
32.
go back to reference Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798–807.CrossRef Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798–807.CrossRef
33.
go back to reference Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008;46:42–9.CrossRef Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008;46:42–9.CrossRef
34.
go back to reference Escudero E, Pena J, Alvarez-Sala R, Vazquez J, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualized therapy. Int J Tuberc Lung Dis. 2006;10:409–14.PubMed Escudero E, Pena J, Alvarez-Sala R, Vazquez J, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualized therapy. Int J Tuberc Lung Dis. 2006;10:409–14.PubMed
35.
go back to reference Rao NA, Irfan M, Mahfooz Z. Treatment outcome of multi-drug resistant tuberculosis in a tertiary care hospital in Karachi. J Pak Med Assoc. 2009;59(10):694–8.PubMed Rao NA, Irfan M, Mahfooz Z. Treatment outcome of multi-drug resistant tuberculosis in a tertiary care hospital in Karachi. J Pak Med Assoc. 2009;59(10):694–8.PubMed
36.
go back to reference Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-West Ethiopia. Tropical Med Int Health. 2017;22(3):351–62.CrossRef Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-West Ethiopia. Tropical Med Int Health. 2017;22(3):351–62.CrossRef
37.
go back to reference Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis. 2006;10:649–55.PubMed Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis. 2006;10:649–55.PubMed
38.
go back to reference Rodriguez M, Monedero I, Caminero JA, Encarnacion M, Dominguez Y, Acosta I, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 2013;17(4):520–5.CrossRef Rodriguez M, Monedero I, Caminero JA, Encarnacion M, Dominguez Y, Acosta I, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 2013;17(4):520–5.CrossRef
39.
go back to reference Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rusch-Gerdes S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: Treatment complexity and XDR-TB among treatment failures. PLoS ONE. 2007;2:e1126.CrossRef Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rusch-Gerdes S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: Treatment complexity and XDR-TB among treatment failures. PLoS ONE. 2007;2:e1126.CrossRef
40.
go back to reference Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Andreev YG, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10:402–8.PubMed Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Andreev YG, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10:402–8.PubMed
41.
go back to reference Albuquerque MF, Ximenes RA, Silva N, Souza WV, Dantas AT, Dantas OM, et al. Factors associated with treatment failure, dropout, and death in a cohort of tuberculosis patients in Recife, Pernambuco state, Brazil. Cad Saûde Pûblica. 2007;23:105–14.CrossRef Albuquerque MF, Ximenes RA, Silva N, Souza WV, Dantas AT, Dantas OM, et al. Factors associated with treatment failure, dropout, and death in a cohort of tuberculosis patients in Recife, Pernambuco state, Brazil. Cad Saûde Pûblica. 2007;23:105–14.CrossRef
42.
go back to reference Chiang CY, Slama K, Enarson DA. Associations between tobacco and tuberculosis. Int J Tuberc Lung Dis. 2007;11(3):258–62.PubMed Chiang CY, Slama K, Enarson DA. Associations between tobacco and tuberculosis. Int J Tuberc Lung Dis. 2007;11(3):258–62.PubMed
43.
go back to reference Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318–26.CrossRef Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318–26.CrossRef
44.
go back to reference Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. EurRespir J. 2013;42(1):156–68.CrossRef Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. EurRespir J. 2013;42(1):156–68.CrossRef
Metadata
Title
Treatment outcomes of drug resistant tuberculosis patients in Morocco: multi-centric prospective study
Authors
Mariam El Hamdouni
Jamal Eddine Bourkadi
Jouda Benamor
Mohammed Hassar
Yahia Cherrah
Samir Ahid
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-3931-5

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.